

WEDNESDAY 18th JULY 2012 COMMENCING 10.30 AM

(UNTIL 4.00 PM APPROX)

AT CARDIFF METROPOLITAN UNIVERSITY, LLANDAFF

CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

- | | | |
|----|--|--|
| 1. | Welcome and introduction | Enclosure |
| 2. | Apologies | |
| 3. | Declarations of interest | |
| 4. | Chairman's report (verbal update) | |
| 5. | Minutes of previous meeting | 1/AWMSG/0712 |
| 6. | Appraisal 1 – Full submission
Darunavir (Prezista[®]) 800 mg once daily , co-administered with low dose ritonavir for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV RNA <100,000 copies/mL and CD4+ cell count ≥100 cells x 10 ⁶ /l | 2/AWMSG/0712
Appendices |
| 7. | Appraisal 2 – Full submission
Dexmedetomidine (Dexdor[®]) for sedation of adult ICU (intensive care unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3) | 3/AWMSG/0712
Appendices |
| 8. | Appraisal 3 – Full submission
Everolimus (Afinitor[®]) for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease | 4/AWMSG/0712
Appendices |
| 9. | Appraisal 4 – Limited submission
Dihydroartemisinin/piperaquine phosphate (Eurartesim[®]) for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more | 5/AWMSG/0712
Appendices |

- | | | |
|-----|--|--|
| 10. | Appraisal 5 – Limited submission
Emtricitabine/rilpivirine/tenofovir (Eviplera®▼) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml | 6/AWMSG/0712
Appendices |
| 11. | Appriaisal 6 – Limited submission
Saxagliptin (Onglyza®▼) for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control | 7/AWMSG/0712
Appendices |
| 12. | Review of AWMSG recommendations | 8/AWMSG/0712 |
| 12. | AWMSG Constitution - update | 9/AWMSG/0712 |
| 13. | Proposal – future of the Wales Patient Access Scheme | 10/AWMSG/0712 |

Date of next meeting:

Wednesday, 12th September 2012 in Abergavenny